- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Dicomit is an antiepileptic drug mainly used to treat Dravet syndrome. It exerts therapeutic effects by regulating GABAergic neurotransmission ...
Dicomit is an antiepileptic drug mainly used to treat Dravet syndrome and refractory epilepsy. It exerts therapeutic effects by regulating GABA...
Lenvatinib is a multi-target tyrosine kinase inhibitor mainly used to treat malignant tumors such as thyroid cancer, hepatocellular carcinoma, ...
Lenvatinib is a multi-target tyrosine kinase inhibitor mainly used for the treatment of malignant tumors such as thyroid cancer, hepatocellular...
Lenvatinib is an oral multi-target tyrosine kinase inhibitor developed by Eisai Corporation in Japan. It is mainly used to treat malignant tumo...
Lenvatinib is an oral multi-target tyrosine kinase inhibitor developed by Eisai Corporation in Japan. It is mainly used to treat malignant tumo...
The standard dose of Ponatinib is 45mg orally once daily, and the specific number of tablets to be taken needs to be calculated according to th...
The treatment cycle of Ponatinib needs to be personalized according to the type of disease, treatment response, and tolerance. It is usually co...
Ponatinib, as a third-generation BCR-ABL tyrosine kinase inhibitor, has significant therapeutic effects on chronic myeloid leukemia (CML) and ...
Whether Ponatinib needs to be taken for a long time depends on the type of disease, treatment response, and individual tolerance. It is usually...
